UNSPSC 51281822: Mitoxantrone dihydrochloride

This classification denotes an anthraquinone compound with the molecular formula C22H28N4O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6USW86RD0, chemically known as 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthraquinone dihydrochloride, but more generally known as mitoxantrone dihydrochloride, which bears US NIH Compound Identifier 4212. European Medicines Agency schedules mitoxantrone dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09012MIG.

Most nations, for tariff purposes, schedule mitoxantrone dihydrochloride under HS 29225000. SMILES: C1CC(C2C(C1NCCNCCO)C(=O)C3C(CCC(C3C2=O)O)O)NCCNCCO.CL.CL.

UNSPSC 51281822 Mitoxantrone dihydrochloride, a Commodity code, shows minimal recent state and local procurement activity directly aligned with the code's scope. The four recent opportunities posted under this code in 2026 predominantly target naloxone and drug deactivation systems, medical and first aid supplies for emergency response, generic pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer pharmacy programs—none of which specifically procure mitoxantrone dihydrochloride, an oncology drug. State and local governments are buying medical supplies, emergency-response consumables, and broad-spectrum pharmaceutical access through wholesalers and direct-contracting models, but the code as currently tagged does not reflect active demand for this specific pharmaceutical ingredient.

Recent opportunities span Florida (Seminole County's naloxone and drug deactivation procurement via IFB), Minnesota and participating states including Oregon through the Minnesota Multistate Cooperative Purchasing Alliance's generic pharmaceutical RFP due March 26, 2026, and Texas (Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs). The City of Tampa issued an IFB for medical and first aid supplies for the Fire Department Rescue Division on March 25, 2026, designated as a sheltered market procurement for certified Small Local Business Enterprises with an estimated contract value of $700,000.00. The mismatch between the code's pharmaceutical specificity and the actual scope of these recent solicitations suggests either misclassification by issuing bodies or limited recent procurement activity for mitoxantrone dihydrochloride itself at the state and local level. Business development professionals should verify whether opportunities in this code tier reflect genuine demand for this drug or whether procurement of oncology pharmaceuticals flows primarily through hospital systems, state Medicaid programs, or federal channels not captured here.